After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis' Epysqli ...

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out and it may have to file for bankruptcy protection. Shares in the South ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...